The current testing rate for BRCA 1/2 mutations is currently 68% in HER2-negative early breast cancer, but eligible patients could receive better care if tested. The current rate of BRCA1/2 testing ...
Harmful variants in the BRCA1 gene greatly increase a person's lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...
The past decade has witnessed a rapid expansion of genetic tests, including new instruments to inform patients who have been diagnosed with breast cancer about the risk of recurrence and to guide ...
An affordable new BRCA gene test has hit the market, but who should take it? — -- A new genetic testing kit that hits the market today is the most affordable, and arguably one of the simplest, ...
ROANOKE, Va. – It’s estimated that more than 42,000 people will die from breast cancer this year, according to the American Cancer Society. To help you understand if you’re at a greater risk of ...
About 1 in 8 women will be diagnosed with breast cancer in her lifetime. But the proportion who develop the common cancer as a result of a genetic mutation — namely to the BRCA1 or BRCA2 genes — is ...
Of the many advances in science and technology over the past 25 years, genetic testing is arguably one of the most notable. Once a rare part of health care, it is now becoming much more common. It’s ...
Should screening for BRCA1/2 mutations be expanded to all women diagnosed with breast cancer? This is the recommendation put forth in recent guidelines from the American Society of Clinical Oncology ...
In May 2013, nearly 20 years after the discovery that mutations on the BRCA1 and BRCA2 genes could lead to a higher risk of breast and ovarian cancer, A-list Hollywood actress Angelina Jolie garnered ...
Lynparza significantly improves iDFS, DDFS, and OS in BRCA1/2 mutation-positive, HER2-negative high-risk breast cancer patients. The trial's six-year analysis shows consistent benefits across all ...
Harmful variants in the BRCA1 gene greatly increase a person’s lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...
Among the 124 undergoing germline testing based on high risk, their average age was 56 (range 34–77). Again, germline BRCA2 variation predominated, with 8 (8%) testing positive, but only one (less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results